In summary, the highly selective BTK inhibitor tirabrutinib exerted an anti-tumor effect via the regulation of multiple BTK downstream signaling proteins, such as NF-κB, AKT, and ERK, in ABC-DLBCL cell lines. This evidence concerns the gene MAPK1 and aneurysmal bone cyst.